Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUP Aurinia Pharmaceuticals		C$0.00	C$11.77 ▼ C$26.00	C$2.15B	N/A	229,895 shs	4.61 million shs
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,224 shs	237,144 shs
TEV Tervita		C$0.00	C$1.69 ▼ C$6.46	C$672.00M	N/A	79,738 shs	15,893 shs
TLRY Tilray Brands	$1.11 +4.7%	$0.63	$0.35 ▼ $1.95	$1.22B	1.85	40.76 million shs	45.89 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUP Aurinia Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+30.85%
TEV Tervita	0.00%	0.00%	0.00%	0.00%	0.00%
TLRY Tilray Brands	0.00%	-15.20%	+57.39%	+137.14%	-43.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TEV Tervita	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	2.4552 of 5 stars	3.1	1.0	0.0	0.0	3.2	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUP Aurinia Pharmaceuticals	0.00	N/A	N/A	N/A
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
TEV Tervita	0.00	N/A	N/A	N/A
TLRY Tilray Brands	2.20	Hold	$1.92	72.67% Upside

Current Analyst Ratings Breakdown

Latest TEV, AUP, CARA, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUP Aurinia Pharmaceuticals	C$57.59M	0.00	N/A	6.75	C$2.59 per share	0.00
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
TEV Tervita	C$1.36B	0.00	N/A	29.62	C$1.58 per share	0.00
TLRY Tilray Brands	$821.31M	1.49	$0.15 per share	7.33	$1.40 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUP Aurinia Pharmaceuticals	N/A	-C$1.48	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
TEV Tervita	N/A	-C$0.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest TEV, AUP, CARA, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
TEV Tervita	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUP Aurinia Pharmaceuticals	2.69	11.93	11.02
CARA Cara Therapeutics	N/A	4.77	4.71
TEV Tervita	440.44	1.00	0.86
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUP Aurinia Pharmaceuticals	N/A
CARA Cara Therapeutics	44.66%
TEV Tervita	N/A
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
AUP Aurinia Pharmaceuticals	N/A
CARA Cara Therapeutics	3.10%
TEV Tervita	N/A
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUP Aurinia Pharmaceuticals	300	128.40 million	N/A	Not Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
TEV Tervita	36,800	115.66 million	N/A	Not Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

TEV, AUP, CARA, and TLRY Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?

5 hours ago | marketbeat.com

Tilray's High Hopes: The Catalyst Driving Cannabis Stocks

...

August 21 at 2:09 PM | marketbeat.com

Top Cannabis Stocks To Watch Today - August 20th

August 21 at 1:11 PM | marketbeat.com

Unleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused Elixir

August 21 at 7:00 AM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Trading Down 7.5% - Time to Sell?

August 20 at 3:05 PM | marketbeat.com

Cannabis Stocks To Follow Today - August 19th

August 20 at 1:01 PM | marketbeat.com

Tilray Shares Blazing: What's Behind the 55% Rally This Month?

...

August 20 at 11:25 AM | marketbeat.com

If You'd Invested $1,000 in Tilray Stock 5 Years Ago, Here's How Much You'd Have Today

August 20 at 7:01 AM | fool.com

Tilray Brands (NASDAQ:TLRY) Shares Up 9.2% - Time to Buy?

August 19 at 3:11 PM | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - August 18th

August 19 at 2:30 PM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's Why

August 19 at 12:47 PM | marketbeat.com

Tilray Brands (NASDAQ TLRY) Rises Amid NASDAQ Composite Market Trends

August 19 at 8:07 AM | kalkinemedia.comK

Promising Cannabis Stocks To Add to Your Watchlist - August 17th

August 18 at 1:51 PM | marketbeat.com

National Bank of Canada FI Sells 763,247 Shares of Tilray Brands, Inc. $TLRY

August 18 at 4:15 AM | marketbeat.com

Tilray Brands (TLRY) Boosts Revenue Mix with New Cannabis, Wellness, and Beverage Products

August 17, 2025 | insidermonkey.com

Cannabis Stocks Worth Watching - August 16th

August 17, 2025 | marketbeat.com

Best Canadian Cannabis Stocks in 2025

August 17, 2025 | marijuanastocks.comM

Tilray Brands (NASDAQ:TLRY) Trading Down 7.2% - Here's What Happened

August 16, 2025 | marketbeat.com

Best Cannabis Stocks To Follow Today - August 15th

August 16, 2025 | marketbeat.com

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

August 15, 2025 | zacks.com

Cannabis Stocks Worth Watching - August 14th

August 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TEV, AUP, CARA, and TLRY Company Descriptions

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Tervita TSE:TEV

Tervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.

Tilray Brands NASDAQ:TLRY

$1.11 +0.05 (+4.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 07:37 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time